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Abstract
Introduction: Previously, secretory phospholipase A2 (sPLA2) inhibition has been used as an adjunct to
conventional rheumatoid arthritis therapy in human clinical trials without significant improvement of arthritic
pathology. In this study, we compared the efficacy of a potent and orally active group IIa secretory phospholipase
A2 inhibitor (sPLA2I) to conventional anti-arthritic agents; infliximab, leflunomide and prednisolone, in a rat model
of antigen-induced arthritis.
Methods: Initially, to establish efficacy and dose-response, rats were orally dosed with the sPLA2I (1 and 5 mg/kg)
two days prior to arthritis induction, and then daily throughout the 14-day study period. In the second trial, rats
were orally dosed with the sPLA2I (5 and 10 mg/kg/day) beginning two days after the induction of arthritis, at the
peak of joint swelling. Separate groups of rats were also dosed with the tumour necrosis factor-alpha (TNF-a)
inhibitor infliximab (single 3 mg/kg i.v. injection), leflunomide (10 mg/kg/day, oral) or prednisolone (1 mg/kg/day,
oral) at this same time point and used as comparative treatments.
Results: In the pathology prevention trial, both 1 and 5 mg/kg dose groups of sPLA2I demonstrated a significant
reduction in joint swelling and gait disturbances; however, only the higher 5 mg/kg dose resulted in significantly
reduced histopathology scores. In the post-induction trial, rats dosed with sPLA2I showed a significant
improvement in joint swelling and gait scoring, whereas none of the conventional therapeutics achieved a
significant decrease in both of these two disease markers. Histopathological scoring at the end-point of the study
demonstrated significantly reduced median scores in rats treated with 10 mg/kg sPLA2I and leflunomide.
Conclusions: The results from this study suggest a pathogenic role for sPLA2 enzymes in this model of arthritis in
rats, and the potential clinical utility of sPLA2 inhibition as a safer, and more effective, alternative to conventional
anti-arthritic therapeutics.
Introduction
Rheumatoid arthritis (RA) is an immune-based chronic
inflammatory synovitis presenting with pain, stiffness and
swelling of the affected joints. RA results in secondary
bone and cartilage destruction causing joint deformity.
Current therapies include conventional non-steroidal
anti-inflammatory agents (NSAIDs), corticosteroids such
as prednisolone, disease-modifying anti-rheumatic-drugs,
such as methotrexate or leflunomide, and biological
therapies such as the inhibitors of tumour necrosis factor
alpha (TNFa), etanercept, adulimumab and infliximab
[1]. No single agent is completely effective at treating dis-
ease pathology and is devoid of side effects; consequently,
a safe and effective treatment for RA remains elusive. In
the mid-1980’s, phospholipase A,2 (PLA2) enzymes were
found to be highly expressed in the synovial fluid of RA
patients [2]. PLA2 forms a group of enzymes that meta-
bolise phosphoglycerides to release lipid mediators such
as lysophospholipids and arachidonic acid. These
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platelet activating factor (PAF) and eicosanoids (prosta-
glandins, thromboxanes, and leukotrienes), respectively
[3]. As opposed to cytosolic PLA2 enzymes which have
physiological functions within virtually all cells [4], secre-
tory PLA2 (sPLA2) enzymes are known to be active dur-
ing inflammation, and thus have been an attractive target
for anti-inflammatory drug development [3]. sPLA2
enzymes also have agonistic activity at the M-type recep-
tor, through which they can promote inflammation via
degranulation of mast cells, cytokine release or secretion
of elastase, an activator of the complement cascade
extrinsic pathway [5-8]. sPLA2 enzyme concentrations
have been found to be elevated in the synovial fluid of
patients with RA [2,9]. Correlations have also been found
between serum levels of sPLA2 and clinical markers of
disease such as the number of active and effused joints,
erythrocyte sedimentation rate, Lansbury index, elevated
platelet count, and low hemoglobin in RA patients
[10,11]. Arthritic joints have also been shown to have
high expression of sPLA2 group IIa within the synovial
lining, while sPLA2 IIa expression in healthy joints is vir-
tually absent [12]. Furthermore, intra-articular injections
of human recombinant sPLA2 caused acute inflammatory
arthritic-like symptoms in rats [13] and rabbits [14],
although transgenic mice over-expressing human sPLA2
did not spontaneously develop arthritis [15,16].
Researchers from Eli Lilly performed a phase I clinical
trial using an inhibitor of sPLA2 group IIa (LY315920)
given intravenously to patients with active RA, which
provided significant improvement in swollen and tender
joints after three days [17]. Following this, a larger scale
Phase II trial was conducted to evaluate the oral efficacy
of LY333013, a methyl ester prodrug of LY315920. The
results from this trial indicated that although there were
significant dose-response related improvements after
one week of treatment, there was no significant effect
following four and eight weeks of treatment [17]. Poten-
tial explanations for this failure include the lack of suffi-
cient inhibitor concentration in the synovial fluid to
inhibit local joint sPLA2, and that all patients were
already receiving disease-modifying anti-arthritic drug
therapy throughout the trial [17,18]. Therefore, there is
still a need to establish whether there may be a patho-
genic role of sPLA2 enzymes in RA.
We have previously reported that a synthetic small
molecule inhibitor of group IIa sPLA2 (sPLA2I; 5-(4-
benzyloxyphenyl)-4S-(7-phenylheptanoylamino)-penta-
noic acid) is orally active and has therapeutic efficacy in
rat models of intestinal ischemia-reperfusion injury [19]
and inflammatory bowel disease [20]. There has also
been evidence of efficacy with this compound in a small,
preliminary investigation in adjuvant-induced arthritic
r a t s[ 2 1 ] .T oe v a l u a t et h i sf i n d i n g ,t h ep r e s e n ts t u d y
reports a full investigation of the potential of this agent
to prevent and reverse signs of inflammatory disease in
the rat antigen-induced arthritis model. In addition, we
compared the in vivo activity of this sPLA2It ot h ec o n -
ventional anti-arthritic agents, infliximab, leflunomide
and prednisolone. In this rodent model of RA, we found
that the sPLA2I reduced all measured markers of arthri-
tis pathology and was more effective than conventional
anti-arthritic treatments.
Materials and methods
Animals
Pathogen-free female Wistar rats weighing 225 to 275 g
were used in this study and housed in cages with 12-
hour light/dark cycles at 23°C, and 60% humidity. All
animal experimentation conducted in this study was
performed in accordance with National Health and
Medical Research Council of Australia guidelines and
with approval from the ethics committee of the Univer-
sity of Queensland.
Model of antigen-induced monoarticular arthritis
Rats were sensitised with methylated bovine serum albu-
min (mBSA; Sigma Aldrich, St Louis, Missouri, USA)) in
0.5 ml Freund’s complete adjuvant (Sigma, USA) as pre-
viously described [22,23]. Injections were administered
subcutaneously in the rat’s flanks, one at three weeks
(Day -21) and the other at two weeks (Day -14) prior to
arthritis induction (Day 0). At Day 0 animals were
anaesthetised with ketamine (80 mg/kg, i.p.) and xyla-
zine (12 mg/kg, i.p.). Arthritis was then induced in the
right knee of each animal by aseptically injecting 0.5 mg
of mBSA dissolved in 50 μLo fs a l i n ei n t ot h ej o i n t
space, while 50 μL of saline was injected into the left
knee as a control.
The widths of both left and right knee joints were
measured with a vernier caliper at regular intervals
before arthritis induction and daily throughout the 14-
day experiment. Following the induction of arthritis, gait
impairment was assessed semi-quantitatively in each
animal, by an investigator blinded to treatment groups.
Animals were scored using a five-point scale (0 to 4)
according to set criteria as previously described [23].
At the completion of the study, the animals were
anaesthetised with intraperitoneal zolazapam (50 mg/kg)
and xylazine (12 mg/kg). Blood was obtained from the
inferior vena cava for the collection of serum and both
left and right knee joints from animals were then dis-
sected and fixed in 10% buffered formalin. Tissues were
decalcified in a saturated EDTA solution for 21 days
and embedded in wax. Sections (5 μm) were stained
with hematoxylin and eosin and examined by a trained
observer who was blinded to the treatments. Each tissue
was scored on the degree of joint damage as previously
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8. Scores of 0 were assigned to normal joints with no
detectable abnormalities while scores increasing from 1
to 8 were reserved for the graded appearance of synovial
cell proliferation, fibrosis, inflammatory cell infiltration,
haemorrhage and cartilage destruction [23]. These para-
meters were chosen as this model of antigen-induced
monoarticular arthritis produces a local inflammatory
response in the affected knee and minimal bone and
cartilage erosion, as has been previously described
[22,23].
TNFa measurement
Serum samples were assayed for TNFa concentrations
using an enzyme-linked immunosorbent assay (ELISA)
kit (BD Pharmingen, Franklin Lakes, New Jersey, USA).
Samples were diluted 1:10 before assay was performed
according to the manufacturer’s instructions.
Drug preparation
The group IIa sPLA2I (5-(4-benzyloxyphenyl)-4S-(7-phe-
nylheptanoylamino)-pentanoic acid), was synthesised as
previously described [20,21]. Leflunomide and predniso-
lone were sourced from Sigma (USA). These com-
pounds were dissolved in olive oil to a final volume of
200 μL and administered by oral gavage. The TNFa
inhibitor, infliximab (Remicade; Schering-Plough, Kenil-
worth, New Jersey, USA) was dissolved in saline and
administered to rats via a single i.v. injection [24,25].
Treatment groups
Two separate experimental trials were conducted to
examine the effects of the therapeutics at preventing
and also reversing disease. In the first “prevention” trial,
rats (n = 10 per group) were orally dosed with the
sPLA2I at either 1 or 5 mg/kg beginning two days prior
to the induction of arthritis (Day -2), and then daily
throughout. An arthritic control group received oral
vehicle (olive oil) doses only.
In the second “reversal” trial, rats (n =7t o1 2p e r
group) were treated with compounds two days following
the induction of arthritis (Day +2), once significant signs
of arthritis were already apparent. The treatment groups
were as follows: A. sPLA2I( 5m g / k g ;n =7 ) ;B .s P L A 2I
(10 mg/kg; n = 7); C. leflunomide (10 mg/kg; n = 10);
D. infliximab (3 mg/kg; n = 8); and E. prednisolone (1
mg/kg; n = 10). Dosages were determined from available
literature (prednisolone: [24,26,27], leflunomide: [28],
infliximab: [24]). All treatment groups were orally dosed
daily throughout the experimental period, except for
infliximab, which was administered once, as an i.v. injec-
tion on Day +2. The arthritic control group (n =1 2 )
was dosed with the vehicle only. Another group of rats
(sham-operated rats; n = 8) did not have arthritis
induced, and were dosed with the vehicle only to deter-
mine increases in knee size and weight gain due solely
to growth.
Data and statistical analysis
Where indicated, values are expressed as mean ± the
standard error of the mean (SEM). Histopathological
scores are presented as individual scores, with median.
Data were analysed using GraphPad Prism 5 software
(GraphPad Software Inc., La Jolla, California, USA). Sta-
tistical comparisons were made using a one-way
ANOVA with a Dunnett post-test, or a Mann-Whitney
U test for histopathology scores. Results were consid-
ered significant when P < 0.05.
Results
Trial 1 (Prevention): The effect of sPLA2I pre-treatment on
joint swelling and gait impairment
Saline-injected left knees of rats did not significantly
change in width from pre-injection values during the
course of each experiment (data not shown). Injection
of mBSA at Day 0 to the right knees of rats resulted in
a significant increase in knee widths over the 14-day
study period (Figure 1A). Rats treated orally with either
dose of sPLA2I (1 or 5 mg/kg) two days prior to the
injection of mBSA (Day -2), and daily throughout, had
significantly reduced knee widths throughout the entire
study (Days 1 to 14) compared to untreated, arthritis
control rats (P < 0.05; Figure 1A).
The induction of arthritis in rats also resulted in con-
siderable gait impairment which was measured via a gait
score (Figure 1B). Rats pre-treated orally with the lower
dose of sPLA2I (1 mg/kg) had significantly reduced knee
widths from Days 3 to 12 compared to untreated, arthri-
tis control rats (P < 0.05; Figure 1B). Rats pre-treated
orally with the higher dose of sPLA2I (5 mg/kg) had sig-
nificantly reduced knee widths throughout the entire
study period (Days 1 to 14) compared to untreated,
arthritis control rats (P < 0.05; Figure 1B).
Untreated, arthritis control rats also lost weight over
t h ec o u r s eo ft h es t u d y( D a y1 4b o d yw e i g h t :3 . 0±1 . 6
grams lost from Day 0 body weight). In contrast, rats
pre-treated with the sPLA2I (1 or 5 mg/kg) gained sig-
nificant weight at the completion of the study (Day 14
body weight: 8.0 ± 2.2 and 6.5 ± 3.1 grams gained
respectively from Day 0 body weight; P < 0.05 compared
to untreated, arthritis control rats; data not shown)
Trial 1 (Prevention): Effect of sPLA2I pre-treatment on
joint histopathology
At the completion of the study, knee joints were examined
histologically and scored on the degree of damage by an
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(Figure 2). All saline-injected, left knees of rats had no
observable pathology (data not shown). The induction of
arthritis to the right knees of rats resulted in distinct cellu-
lar infiltration, which was predominantly neutrophils, with
synovial cell proliferation and hyperplasia. Cartilage ero-
sions, however, were minimal. Rats orally pre-treated with
the sPLA2I at the higher dose (5 mg/kg) had significantly
reduced joint histopathology scores compared to
untreated, arthritis control rats (P < 0.05; Figure 2). In
contrast, rats pre-treated with the lower dose of the
sPLA2I (1 mg/kg) did not show a significant reduction in
joint histopathology scores (P > 0.05; Figure 2).
Trial 1 (Prevention): Effect of arthritis induction on
circulating cytokine levels
At Day 14, serum from diseased- and sham-treated rats
showed no significant difference in TNFa concentra-
tions (0.41 ± 0.02 and 0.37 ± 0.01 respectively; P =
0.69). These data are in accordance with previous
research that describes this model as a local, rather
than systemic, model of RA [22]. Therefore, it was
decided not to apply this measurement to future
experiments.
AB
Figure 1 Effect of sPLA2I pre-treatment on joint swelling and lameness. Right knee joints of all sensitised rats were injected with antigen
on Day 0. Knee widths (A) and gait scores (B) were recorded for each rat over 14 days. Treatment was commenced two days prior to arthritis
induction and daily throughout. (A) Both oral doses of the sPLA2I resulted in a significant reduction of knee swelling throughout the study
period. (B) Both oral doses of the sPLA2I resulted in a significant reduction of gait scores at various time points over the study period. Each data
point represents the mean ± SEM. Lines indicate the period of significance (P < 0.05) between arthritis control and (A) both treatment groups;
(B) dotted line - sPLA2I (5 mg/kg); solid line - sPLA2I (1 mg/kg).
Figure 2 Effect of sPLA2I pre-treatment on histopathology of
joint. At the completion of the 14-day pre-treatment study all
arthritic knee joints were removed and prepared for histological
evaluation. Knee sections were scored (0 to 8) for the degree of
cellular infiltration, synovial hyperplasia, cartilage damage and bone
erosions. Only rats orally treated with the sPLA2I at 5 mg/kg/day
showed a significant reduction in histopathology scores. Each data
point represents a specific score with the median shown.
** indicates significant difference (P < 0.01) between arthritis
controls and treatment group using the Mann-Whitney U test.
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swelling and gait impairment
Treating animals two days following the induction of
arthritis (Day +2) and daily throughout the study with
the sPLA2I (5 and 10 mg/kg) significantly ameliorated
joint swelling throughout the entire study period follow-
ing treatment (P < 0.05, Days 3 to 14; Figure 3A). Ani-
mals treated from Day +2 with the various comparator
drugs: leflunomide (10 mg/kg), infliximab (3 mg/kg),
and prednisolone (1 mg/kg) also had significant reduc-
tions in joint swelling, although for a reduced time per-
iod than the sPLA2I( P < 0.05, leflunomide (Days 4 to
8), infliximab (Days 3 to 8), prednisolone (Day 10);
Figure 3B).
Gait scores significantly improved following treatment
with either dose of the sPLA2I( 5o r1 0m g / k g )f r o m
Day +2 (P < 0.05, Days 4, 10, 12; Figure 3C). Animals
treated with the various comparator drugs from Day +2
also had significant reductions in gait scores, although
again for a shorter time period than the sPLA2I( P <
0.05, leflunomide (Days 6, 8), infliximab (Days 6 to 10),
prednisolone (Day 4); Figure 3D).
Joint swelling and gait scores were assessed over the
entire trial period by comparing area under the curves
from Figure 3. Overall, throughout the trial period, only
sPLA2I( 5o r1 0m g / k g )s h o w e das i g n i f i c a n td i f f e r e n c e
in both knee width and gait score (5 mg/kg: P <0 . 0 0 1
and 0.01; 10 mg/kg P < 0.01 and 0.05; Figure 4). Inflixi-
mab demonstrated an overall significant decrease in
knee width (P < 0.05) and prednisolone demonstrated
an overall decrease in gait score (P < 0.05); leflunomide
did not reach significance for either parameter (P >
0.05; Figure 4).
Trial 2 (Reversal): Effect of drug post-treatment on body
weight loss
Rats were weighed throughout the experiment, with
final day (Day +14) weights expressed as a change in
AB
CD
Figure 3 Effect of post-treatment on joint swelling and lameness. Right knee joints of all sensitised rats were injected with antigen on Day
0. Treatment was commenced two days following arthritis induction. Knee widths (A, B) and gait scores (C, D) were then recorded for each rat
and are displayed as a change in these parameters from point of treatment (Day 2). Treatment with the sPLA2I at both doses (5 and 10 mg/kg)
resulted in a significant reduction in joint swelling (A) (P < 0.05; Days 3 to 14) and gait scores (C) (P < 0.05; Days 4, 10, 12). Treatment with the
comparator drugs (leflunomide, infliximab and prednisolone) also resulted in significant reductions (P < 0.05) in joint swelling (B) and gait scores
(D) although to a lesser extent than the sPLA2I (knee widths: leflunomide (Days 4 to 8), infliximab (Days 3 to 8), prednisolone (Day 10); gait
scores: leflunomide (Days 6, 8), infliximab (Days 6 to 10),to prednisolone (Day 4)). Each data point represents the mean ± SEM.
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between the various groups (Figure 5). Untreated, arthri-
tis control rats had a total weight loss over the 14 days,
and had significantly reduced weight compared to un-
diseased, sham-operated rats (P < 0.05; Figure 5). All
drug treatments, with the exception of prednisolone,
resulted in an increase in weight after 14 days, though
none were significantly increased from untreated,
arthritic control rats (P > 0.05; Figure 5. Prednisolone-
treated rats showed considerable weight loss over the
study period, and after 14 days had significantly reduced
weight compared to untreated, arthritic control rats (P <
0.05; Figure 5).
Trial 2 (Reversal): Effect of drug post-treatment on joint
histopathology
Histological analysis and scoring of diseased joints for
untreated, arthritic control rats showed a similar degree
of pathology compared to the same group in the first
trial (Figure 6). Similarly, only rats treated with
the higher dose of sPLA2I( 1 0m g / k g )s h o w e das i g n i f i -
cant reduction in histopathological scores (P <0 . 0 5 ;
Figure 6), although a reduction in median histopatholo-
gical scores was seen with the lower sPLA2I( 5m g / k g ) .
Leflunomide treatment also resulted in a signifi-
cant improvement in histopathology scores (P <0 . 0 5 ;
Figure 6). Rats treated with infliximab showed a non-
significant reduction median scores, (P > 0.05; Figure 6)
and rats treated with prednisolone showed a clear lack
of benefit, with no significant reductions in these scores
(P > 0.05; Figure 6).
Discussion
This study is the first investigation of sPLA2 IIa inhibi-
tion in the antigen-induced arthritis model of RA. We
have previously demonstrated the usefulness of this
model in establishing the efficacy of other experimental
compounds and conventional anti-inflammatory drugs
[23]. In the present study we have compared the efficacy
of sPLA2 group IIa enzyme inhibition, using an orally-
active and specific small molecule sPLA2I, with currently
used anti-arthritic drugs in reducing antigen-induced
arthritic pathology. We demonstrate that inhibition of
sPLA2 IIa alleviates the clinical signs and pathological
changes associated with RA, with a greater reliability
than some conventional anti-rheumatoid therapies.
sPLA2 IIa is a secretory enzyme that converts arachi-
donic acid (AA)-containing phospholipids to free AA,
and has been shown to be highly expressed in affected
joint tissues in patients with RA [12]. sPLA2 IIa forms
the apex of an autacoids cascade in the synovium of
arthritic joints. The heparin binding domain of sPLA2
localises to lipid rafts, bringing the enzyme into close
proximity to downstream mediators of this cascade,
such as cycloxygenase and lipoxygenase [29]. Addition-
ally, sPLA2 IIa is a ligand for the M-type receptor
CD
B A
Figure 4 Effect of post-treatment on joint swelling and lameness throughout the study period. Right knee joints of all sensitised rats
were injected with antigen on Day 0. Treatment was commenced two days following arthritis induction. Representative reduction in knee width
(A) and gait score (B) throughout the trial period (Days 0 to 14) was attained by calculating the average area under the curve of data displayed
in Figure 3. sPLA2I treatment at 5 or 10 mg/kg achieved a significant reduction in both joint swelling (P < 0.001 and P < 0.01 respectively) and
lameness (P < 0.01 and P < 0.05 respectively) over the trial period (A, B). Infliximab significantly reduced joint swelling (P < 0.05) without
effecting lameness (A), and prednisolone significantly reduced lameness (P < 0.05) without effecting swelling (B). Each column represents mean
± SEM.
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change in body weight from Day 0 recorded every 48 hours for 14 days. Treatment was commenced two days following arthritis induction. The
panels show: (A) Body weight over time for all treatment groups. (B) Change in body weight from baseline values. Arthritis control rats lost
weight after 14 days, while all treatment groups gained weight, except for prednisolone-treated rats which lost considerable weight. Each data
point represents the mean ± SEM. (P < 0.01). Significant differences from sham-operated rats (#) and arthritis controls (*) are indicated (P < 0.01).
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M-type receptor in mast cells results in degranulation
[30]; in neutrophils it mediates an increase in cPLA2
[29]; and in monocytes induces exocytosis of cytokines,
including TNFa [31]. Current RA therapies, such as the
TNFa inhibitor, infliximab, or the NSAID, ibuprofen,
target the mediators downstream of sPLA2 IIa. Specific
inhibition of sPLA2 IIa may, therefore, be a valid target
to develop novel disease modifying anti-rheumatic drugs
(DMARDs) which are more efficacious than existing
therapies, given high concentrations of sPLA2 IIa in
arthritic joints [23]. This study confirms this hypothesis
demonstrating that an orally-active sPLA2Ii nar a t
model of RA provides significant benefits over inhibition
of downstream mediators of inflammation currently
used as standard therapies in the treatment of RA.
In this study, we used a potent and orally active inhi-
bitor of group IIa sPLA2 enzymes (sPLA2I) [20,21]. Oral
administration of this drug to rats, prior to the induc-
tion of arthritis and daily throughout the trial, was
found to be effective at reducing joint swelling and gait
score when administered at both 1 and 5 mg/kg/day.
However, sPLA2I at the lower 1 mg/kg dose failed to
reduce the disease progression as demonstrated by his-
topathology, when compared to untreated controls.
Therefore, doses of 5 and 10 mg/kg/day were used to
examine efficacy of reversing established arthritic
damage. It is likely that the effect of sPLA2Id e m o n -
strated in the prevention trials is due to action on the
effector, rather than induction-phase of the immune
response as rats were pre-sensitised to the antigen at
-21 and -14 days. However, the design of this study did
not allow us to discriminate between the action of the
drug on both phases. In the reversal therapeutic trial,
sPLA2I was compared to conventional arthritis treat-
ments infliximab, leflunomide and prednisolone. Rats
were treated from Day 2, as this is near the maximal
response in knee swelling and gait scores as seen in our
first experimental trial. A separate group of rats eutha-
nased at Day 2 showed a significant degree of histo-
pathological damage (data not shown) validating the
choice to initiate treatment at this time point.
Both 5 and 10 mg/kg/day sPLA2I significantly reduced
both gait score and joint swelling over the course of the
study in the reversal trial. Of the conventional treat-
ments, although all were ablet od e m o n s t r a t eas i g n i f i -
cant benefit at certain individual time points, only
infliximab reduced inflammation (knee width) and pre-
dnisolone reduced pain (gait score) with overall statisti-
cal significance. Additionally, treatment with infliximab
or prednisolone showed no significant reduction in his-
topathology score, but both leflunomide and sPLA2I
(10 mg/kg/day) were effective in reducing the joint
histopathology to a significant degree. Overall, sPLA2I
alleviated all aspects of RA pathology with a greater
reliability than any of the conventional therapeutics in
this study.
The success of targeted sPLA2 IIa inhibition with the
sPLA2I used in this study could be attributed to the
actions of sPLA2 I I au p s t r e a mo fm a n yo ft h et a r g e t so f
the conventional therapies. For instance, the binding of
sPLA2 IIa to the M-type receptors has been shown to
cause TNFa, IL6 and IL12 release from monocytes [32];
in this way sPLA2I has clinical similarities to those of
infliximab, a TNFa inhibitor. Additionally, sPLA2 inhibi-
tion prevents mast cell degranulation by inhibiting
sPLA2 IIa interaction with the M-type receptor [6]
whereas leflunomide induces mast cell apoptosis [33].
Mast cells have been postulated as the link between the
antigen-antibody complex triggered inflammation and
sustained, chronic RA, as mast cell deficient mice are
resistant to the development of RA in an arthritogeneic
serum model [29]. This mechanism could explain the
success of early leflunomide intervention in clinical
trials, and the significant reduction in histopathology
score, by both sPLA2I and leflunomide, in this study
[34,35]. We have previously demonstrated that another
commonly used anti-arthritic agent, ibuprofen, was
unable to reduce the degree of histological damage in
the same model, despite providing a therapeutic effect
Figure 6 Effect of post-treatment on histopathology of joint.A t
the completion of the 14-day post-treatment study all arthritic knee
joints were removed and prepared for histological evaluation. Knee
sections were scored (0 to 8) for the degree of cellular infiltration,
synovial hyperplasia, cartilage damage and bone erosions. Rats
treated with the sPLA2I (5 mg/kg) and infliximab showed reduced
median scores compared to controls, though no significance was
obtained. Treatment with sPLA2I (10 mg/kg) and leflunomide
exhibited significantly reduced histopathology scores (P < 0.05,
Mann-Whitney U test). Each data point represents the specific score
with the median shown.
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trast to leflunomide, which was able to reduce histo-
pathology without providing an overall significant
benefit to gait score and joint swelling after Day 8. Inhi-
bition of sPLA2 IIa, however, caused significant reduc-
tions in gait score, joint swelling and histopathology.
This is evidence that each of these facets of RA is
mediated by separate, but communicating, mechanisms.
sPLA2 inhibition reduces prostaglandin synthesis by
COX, through reducing the concentration of free AA,
whilst ibuprofen is a direct inhibitor of COX. This inhi-
bition of prostaglandin synthesis, which both reduces
inflammation and inhibits pain, may account for the sig-
nificant difference seen in gait scores/joint swelling with
both these drugs. Inhibition of sPLA2 IIa also reduces
mast cell degranulation and neutrophil infiltration by
preventing binding to M-type receptors [33]. This
attenuation of immune cell function may mimic the
mast cell-specific repression of leflunomide, which
causes cell cycle arrest and mast cell apoptosis, in alle-
viating joint histopathology [33]. The multiple actions of
sPLA2 IIa in arthritis, and its absence in the synovium
of healthy joints, are likely the reason for its success in
this study when compared to conventional therapeutics.
In addition, conventional therapeutics, with the excep-
tion of prednisolone, target single downstream media-
tors of sPLA2 IIa actions.
Specific inhibition of sPLA2 enzymes has an advantage
over conventional RA therapeutics, in that it targets mul-
tiple possible pathways of RA pathogenesis (Figure 7),
without affecting normally occurring biological processes.
There have been no demonstrated side effects of sPLA2
IIa inhibition in animal models of disease and the
phase II clinical trial of an sPLA2Ii nh u m a n sp r o v i d e d
evidence of some liver toxicity only at the highest doses
(1,000 mg/day) [17]. Conversely, all conventional thera-
peutics in this study failed to show significant benefit to
every pathology measurement of the antigen-induced
arthritis model. In addition, many of the conventional
therapeutics have off-target effects that mitigate the ben-
efits provided. Leflunomide and infliximab have been
shown to inhibit osteogenic cell proliferation [36];
because of this, both treatments pose additional risks for
post-menopausal women. Leflunomide and prednisolone
Figure 7 Simplified hypothetical model demonstrating the sites of action of anti-arthritic therapeutics used in this study.s P L A 2 IIa
provides the substrate for the production of the inflammatory mediators; platelet-activating factor (PAF), prostaglandins and leukotrienes.
Additionally, sPLA2 IIa is a ligand for the M-type receptor: sPLA2 IIa agonist activity causes mast cell degranulation and activation of neutrophils.
Ibuprofen, leflunomide and infliximab all act on inflammatory mediators downstream of sPLA2 IIa actions. Prednisolone globally alters
inflammatory gene transcription. AA, arachidonic acid; cPLA2, cytosolic phospholipase A2; PAF, platelet activating factor; MAP kinase, mitogen
activated protein kinase; M-type receptor, muscle type receptor; sPLA2 IIa, secretory phospholipase A2 group IIa; TNFa, tumour necrosis factor
alpha.
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induces the apoptosis of several types of immune cells
[33,37,38], and prednisolone induces cell cycle arrest,
thereby inhibiting cellular proliferation. This study also
confirms a catabolic effect of daily prednisolone adminis-
tration as has been previously shown [24] and, although
prednisolone can act as an inhibitor of sPLA2 IIa tran-
s c r i p t i o n[ 3 9 ] ,t h eu s eo fal o w - d o s es t e r o i di nac h r o n i c
condition can potentiate morbidity for the patient
[40-42].
Previously, the efficacy of sPLA2 IIa inhibition has
been tested in phase II clinical trials as an adjunct to
DMARD therapy without success [17]. The administra-
tion of DMARDS in conjunction with the sPLA2Im a y
have masked any benefits provided by sPLA2I. Here we
show, for the first time, that sPLA2 IIa inhibition has
the potential to be a useful monotherapy for the treat-
m e n to fR A ,a n dm a yb eam o r ee f f e c t i v ec h r o n i ct h e r -
apy than the conventional RA therapeutics.
Conclusions
We have previously shown the sPLA2I used in this study
to be an orally-active, highly selective drug for the treat-
ment of intestinal ischemia reperfusion injuries [19] and
inflammatory bowel disease [20] in rat models, and now
demonstrate its efficacy in a model of RA. Inhibition of
sPLA2 IIa using a chemically different sPLA2 enzyme
inhibitor, has previously been trialed in human RA. In
this clinical trial, the sPLA2 inhibitor was administered
as an adjunct therapy to DMARD and glucocorticoid
therapy, which may have masked any benefits to
patients [17]. By directly comparing sPLA2 inhibition to
conventional therapies in a rodent model of antigen-
induced arthritis, we have provided a rationale and
evidence for the use of sPLA2I as a replacement for
DMARD/glucocorticoid therapy in future clinical trials.
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